

Index

Note: Page numbers of article titles are in **boldface** type.

- ADRENAL glands, and Hodgkin's disease, 99
- Albumin, in Hodgkin's disease, 112
- Alcohol-induced pain, in Hodgkin's disease, 109-110
- Alpha-chain disease, 13
- Amino acids, and Hodgkin's disease, 111
- Amyloidosis, and Hodgkin's disease, 112
- Antibodies, in Hodgkin's disease, 119
- Anticonvulsants, and malignant lymphomas, 29-30
- Antigens, in Hodgkin's disease, 119
- Appendectomy and Hodgkin's disease, 15
- Autoimmune disease—
 - and Hodgkin's disease, 120
 - and malignant lymphoma, 27-29

- BLOOD chemistries, 84
- Bone marrow, and Hodgkin's disease, 102-103
- Bone marrow biopsy, in non-Hodgkin's lymphoma, 137-141
- Bone marrow evaluation, 80
- Bones, and Hodgkin's disease, 103-104
- Burkitt's lymphoma, chemotherapy and, 207
- Burkitt's tumour, 59-60

- CALCIUM, and Hodgkin's disease, 110
- Cells—
 - red blood, and Hodgkin's disease, 113-115
 - white blood, and Hodgkin's disease, 115
- Cellular immunity, failure of, in Hodgkin's disease, 117-119
- Central nervous system—
 - and Hodgkin's disease, 104-107
 - involvement in non-Hodgkin's lymphoma, 151-152
- Chemotherapy—
 - as primary treatment for Hodgkin's disease, 197
 - Burkitt's lymphoma and, 207
 - choice of in Hodgkin's disease, 197-202
 - choice of patients with non-Hodgkin's lymphoma for, 208
- Chemotherapy—(*continued*)
 - combination, 198-200
 - in non-Hodgkin's lymphomas, 154, 202-208
 - single-agent, 197-198
 - treatment of patients in whom quadruple is ineffective, 201
- Childhood lymphosarcoma, chemotherapy and, 207
- Clinicopathologic correlations, 64-68
- Cytogenetics of lymphomas, 9-10

- DERMATOMYOSITIS, and Hodgkin's disease, 109
- Drug administration and toxicity in Hodgkin's disease, 200-201

- ENZYMES, and Hodgkin's disease, 113
- Epitrochlear lymphadenopathy, in non-Hodgkin's lymphomas, 151
- Epstein-Barr virus and malignant lymphomas, 17-19
- Erythrocyte sedimentation rate in Hodgkin's disease, 117
- Extralymphatic disease, localised, and initial stage of involvement in non-Hodgkin's lymphomas, 143-144

- FEVER, and Hodgkin's disease, 108-109

- GASTROINTESTINAL tract—
 - and Hodgkin's disease, 96
 - involvement in non-Hodgkin's lymphoma, 148-151
- Genitourinary tract, and Hodgkin's disease, 104
- Globulins, in Hodgkin's disease, 112

- HAEMATOPOIETIC diseases, 39
- Heart as site of Hodgkin's disease, 95
- Hepatic Hodgkin's disease, 101-102

- Histiocytic lymphomas, 57-59
- Histopathology of malignant lymphomas, 39-69
- Hodgkin's disease, 61-63
 and other lymphomas, staging of, 77-88
 and skin lesions, 107
 cellular basis of, 5-7
 chemotherapy for, 195-202
 classification of, 77-80
 clinical features and course of, 91-120
 clinical stages I and II, radiotherapy and, 165-172
 clinical stages III and IV, radiotherapy and, 180-183
 clinicopathic studies, 64-66
 complications, 108-117
 complications due to metabolic and endocrine abnormalities, 110-113
 delayed hypersensitivity in, 117-118
 drug-induced effects of, 106-107
 epidemiology of, 11-12
 familial, 20-21
 haemotogenous spread of, 100-107
 haematologic complications, 113-117
 histocompatibility antigens and, 21-22
 immune responsiveness in, 24-25
 immunologic complications, 117-120
 immunological factors and radiotherapy, 177
 mediastinal involvement, and radiotherapy, 177-179
 neurological complications of, 104-105
 non-specific clinical manifestations of, 108-110
 of the lungs, 93-95
 origin and progression, 92
 pathology of, 4-7
 radiotherapy in, 161-183
 radiotherapy and correlation of occult disease and clinical data, 174-176
 radiotherapy and liver involvement, 174
 radiotherapy and the extent of inter-abdominal lesions, 173-174
 retroperitoneal and intra-abdominal, 95-99
 sites of, 92-108
 surgery, 86-88
 techniques of radiotherapy in, 162-165
 tentative classification, 179-180
 tissue-associated antigens, 19-20
 tonsillectomy, appendicectomy and the development of, 15
 transmissibility of, 14-15
 treatment of patients in whom quadruple chemotherapy is ineffective, 201
 use of drugs in, 196-197
- Homograft rejection in Hodgkin's disease, 118
- Hormones, and Hodgkin's disease, 113
- Hydroxyproline, and Hodgkin's disease, 111-112
- Hypertrophic osteoarthropathy and Hodgkin's disease, 110
- IMMUNE responsiveness in Hodgkin's disease, 24-25
- Immune-complex nephritis, 29
- Immunodeficiency states and lymphomas, 25-27
- Immunologic deficiencies and diseases, and Hodgkin's disease, 119-120
- Infections, and Hodgkin's disease, 105-106, 118-119
- KAPOSI's sarcoma, 13-14
- LAPAROTOMY, in non-Hodgkin's lymphomas, 142-143
- Leucocyte HL-A phenotypes in Hodgkin's disease, 115-116
- Liver, and Hodgkin's disease, 101-102
- Liver biopsy in non-Hodgkin's lymphomas, 141-142
- Lymphocytes in Hodgkin's disease, 116-117
- Lymphocytic-histiocytic lymphomas, mixed, 56-57
- Lymphocytic lymphomas—
 poorly differentiated, 55
 well-differentiated, 54-55
- Lymphoma—
 and alpha-chain disease, 13
 anatomical site, and histological type of, 9
 non-Hodgkin's, radiotherapy and, 183-190
 primary intestinal, 12-13
 undifferentiated non-Burkitt's, 61
- Lymphoma induction, chronic graft-v-host reaction and, 22-24
- Lymphomas—
 aetiologic leads in the malignant, 3-31
 and Kaposi's sarcoma, 13-14
 anticonvulsants, and malignant, 29-30
 autoimmune disease and malignant, 27-29
 chemotherapy of the, 195-208
 classification of malignant, 44, 46, 49-51
 clinical features and course of non-Hodgkin's, 131-158
 clinicopathic studies of non-Hodgkin's, 66-68
 cytogenetics, 9-10
 diffuse, 157-158
 diffuse malignant, 53-61
 epidemiology, 10-14

Lymphomas—(continued)

- Epstein-Barr virus and malignant, 17-19
- histopathology of malignant, 39-69, 51-64
- historical observations and concepts of malignant, 42-49
- immunodeficiency states and, 25-27
- immunologic aspects of malignant, 19-29
- impaired immune function and the development of, 22
- inherent and acquired susceptibility to the development of, 20
- nodular, 158
- nodular (follicular), 51-53
- non-Hodgkin's, 7-8 (*see also* non-Hodgkin's lymphomas)
- non-Hodgkin's, epidemiology of, 12
- pathology of malignant, 4-8
- radiotherapy in the treatment of malignant, 161-190
- role of external factors in, 10-19
- surgery and, 86-88
- viral aetiology and, 15-19
- Lymphoreticular neoplasms, 39-42
- Lymphosarcoma, childhood, chemotherapy and, 207

MALIGNANT lymphomas, pathology of, 4-8
Mediastinum site of Hodgkin's disease, 93
Metabolic effects of Hodgkin's disease, 106
Metals and Hodgkin's disease, 110-111
Mycosis fungoides, 61

NEPHRITIS, immune-complex, 29

Nephrotic syndrome, and Hodgkin's disease, 120

Nodular (follicular) lymphoma, 51-53

Non-Hodgkin's lymphoma—
age and sex at diagnosis of, 145
choice of patients with, for chemotherapy, 208
clinical and laboratory investigations of Stages I and II, 184-185
clinical features and course of, 131-158
clinical staging, 137-145
constitutional symptoms, 146
correlation between survival and histologic type, 135-137
diffuse or disseminated forms (Stages III and IV), 188-190
evolution and prognosis, 187-188
histopathology of, 131-137

Non-Hodgkin's lymphoma—(continued)

- immunological features, 152-153
- intrathoracic manifestation of, 146-147
- local and regional forms (Stages I and II), 184-188
- mode of spread, 144-145
- natural history and interpretation of treatment results, 153-157
- radiotherapy and, 183-190
- results of radiotherapy, 185-187

PERICARDIUM site of Hodgkin's disease, 95

Phosphorus, and Hodgkin's disease, 110

Pruritus, and Hodgkin's disease, 109, 111

Pyrimidines, and Hodgkin's disease, 111

RADIATION therapy in non-Hodgkin's lymphomas, 154-157

Radiographic evaluation, 81-84

Radiotherapy—

- chemotherapy as adjuvant treatment to, 196-197

- in the treatment of malignant lymphoma, 161-190

Reticuloendothelial malignancies, 39-42

SCANNING and nuclear medicine, 84-86

Skin lesions and Hodgkin's disease, 107

Skin testing, 84

Spinal cord, and spread of Hodgkin's disease, 97

Spleen, as site of Hodgkin's disease, 99-100

Splenectomy, in non-Hodgkin's lymphomas, 142-143

Staging of Hodgkin's disease and other lymphomas, 77-88

Subdiaphragmatic disease, 188

THYMUS, as site of Hodgkin's disease, 95

Tonsillectomy and Hodgkin's disease, 15

URIC acid, and Hodgkin's disease, 111

VIRAL aetiology of lymphomas, 15-19

WALDEYER's ring, involvement of in non-Hodgkin's lymphomas, 147-148

Index

Note: Page numbers of article titles are in **boldface** type.

This index does not contain an exhaustive list of the haemoglobin variants mentioned in the text. A full list of haemoglobin mutants appears in Tables 2-6, pp. 256-265.

- ACID-elution technique for fetal haemoglobin, 545
- Africans, α thalassaemia among, 278
- Alkali-denaturation procedures for fetal haemoglobins, 546-547
- Allosteric effectors, 365
- α chain, 216, 250-251
 - excess in β thalassaemia, 414-416
 - of Hb F, genetic control of, 472
 - variants, 270-271, 498
- α -globin-gene duplication, 447-448
- α thalassaemia, *see* thalassaemia, α
- Amino acid—
 - deletions, 262-264, 335-336
 - replacement at haem-contact, 335
 - replacement by proline, 339
 - substitutions, 262
- S2 γ aminoethyl derivative of α or non- α chain, formation of, 562
- Anaemia—
 - aplastic, haemoglobin F in, 492-493
 - in sickle cell, 288-322
 - in α thalassaemia, 387, 391
 - in β thalassaemia, 419, 427
 - refractory, with hyperplastic bone marrow, haemoglobin F in, 493-494
- Anion-exchange chromatography, 538-540
- Antenatal diagnosis of haemoglobinopathies, 522-523
- Aplastic crises in sickle-cell anaemia, 312
- Autohaemolysis test in unstable haemoglobin disorders, 347
- β CHAIN—216, 250-251
 - deficiency, in β thalassaemia, 412-414
 - variants, 269-270, 557-558
- β thalassaemia, *see* thalassaemia, β
- Blood, collection, transportation, and preparation of for haemoglobin analysis, 529
- Blood transfusion, in α thalassaemia, 406
- in β thalassaemia, 429-431
- Bohr effect, and abnormalities of haemoglobin, 368-370
- Bohr protons, 362-363
- Bone infarcts, sterile, in sickle-cell anaemia, 313
- CATION-exchange chromatography, 536-538
- Cell membrane, in β thalassaemia, 417
- Cellulose-acetate electrophoresis, 532-533
 - and isoelectrofocussing, 543
- Chains—
 - see* individual chains, i.e. α -, β -, δ -, γ -, etc.
- Chains, globin—
 - elongation in protein synthesis, 232
 - identification after PMB treatment, 561
 - initiation in protein synthesis, 230-232
 - separation—
 - by column chromatography, 561
 - by counter current distribution, 561
 - termination in protein synthesis, 233-234
 - termination mutants, 264
- Cholelithiasis, 407
- Chromatographic methods—
 - Amberlite IRC 50, 538
 - CM-cellulose, 536
 - DEAE-sephadex, 542-543
 - DE-52-cellulose, 542
 - evaluation of methods, 540-541
 - in determination of fetal haemoglobin, 547
 - in diagnosis of haemoglobinopathies, 536-541
 - separation of chains by, 561
- Chromosomal anomalies, fetal haemoglobin levels with, 488
- Chromosomal location, linkage between genes and, 254-255
- Chromosomal proteins, 438-440
- Chromosomal organisation, 438-441
- Contacts, subunit, substitution of amino acids in, 339
- Cord-blood samples, detection of abnormal haemoglobins in, 556-558
- Crossing-over, mechanism of, 446-447
- Cyanate, and sickling, 320

- DACTYLITIS in sickle-cell disease, 312
 δ -chain variants, 271
 δ thalassaemia, 275
 $\delta\beta$ thalassaemia, 274-275
 Diagnosis of the haemoglobinopathies, 527-564
 antenatal, 509-564
 DNA in chromosomes, 438
 2,3-diphosphoglycerate—
 binding, abnormalities involving the sites of, 370
 determination of, 558-559
 effect on haemoglobin function, 221, 365, 468
 metabolism, abnormalities of, 374
 ELECTROPHORESIS, haemoglobin, 346-347, 585-586
 evaluation of methods, 535-536
 in diagnosis of haemoglobinopathies, 530-536
 'Erythron', in β thalassaemia, 417-422
 Erythropoiesis, transcriptional unit and, 444
 Erythropoietin metabolism, abnormalities of, 374-375
 Eukaryotic cells, regulatory genes in, 443-444
 FERRARA, β thalassaemia in, 457
 Fetal erythropoiesis and the developmental sequence of the embryonic and fetal haemoglobins, 470-472
 Fetal haemoglobin, *see* Haemoglobin F
 Folic-acid deficiency in sickle-cell disease, 313
 Frame-shift mutants, 264-266
 F thalassaemia, 274-275
 Fusion chain variants, 266-269, 499, *see also* Haemoglobin Lepore; Haemoglobin Kenya
 γ CHAIN—
 control of, 472-475
 variants, 271, 498, 556, 557
 γ thalassaemia, 276
 $\gamma\beta$ thalassaemia, 500
 Gene—
 deletion and thalassaemia, 450-451
 frequency, 441-442
 mutations affecting two non-allelic, 271
 recombination, 445-451
 significance of, 447
 regulatory, in eukaryotic cells, 443-444
 regulatory, the operon, and thalassaemia, 445
 structural haemoglobin genes and their regulation, 252-254
 Genetic control—
 of adult haemoglobins, 251-280
 Genetic Control—(continued)
 of fetal haemoglobins, 472-475
 of haemoglobin in thalassaemia, 276-277
 Globin—
 structure of, 219-220
 synthesis, 229-235, 387
 Glycogen, red-cell, in β thalassaemia, 417
 Greek form of hereditary persistence of fetal haemoglobin, 482-486
 HAEM contact amino acids, replacement of, 335
 Haem-haem interaction, 363, 365
 Haem-pocket—
 abnormalities of, 367-368
 structure of, 218-219
 Haem-protein ratio, determination of, 553-554
 Haem synthesis, 228-229
 Haematuria, 316
 Haemichromes, role of in denaturation of unstable haemoglobins, 351
 Haemodynamics and oxygen transport, 299-300
 Haemoglobin—
 abnormal, 262-269, 367-374
 electrophoresis, 346-347
 genetic control of, 251-280
 normal human, 216, 251-255
 with abnormal oxygen transport, 357-382
 structure and function of, 217-222, 356-367
 synthesis, 225-243
 hereditary abnormalities of, 272-279
 regulation of, 235-243
 switch from fetal to adult, 477-481
 unstable, 333-353
 bone marrow in, 342-345
 clinical features and laboratory findings, 339-348
 complications and treatment, 349-350
 differential diagnosis, 348
 genetic features, 339-341
 Hb-A₂ and Hb-F levels, 347
 heat denaturation test in, 345
 Haemoglobin A₂, 216
 determination of, 542-544
 variants, of 271
 in β thalassaemia, 413
 Haemoglobin Bart's, 499-500, *see also* thalassaemia, α
 hydrops fetalis, 387-390
 in newborn period, 386
 haemoglobin A + Bart's disease, 395
 haemoglobins A + E + Bart's disease, 398
 haemoglobins E + F + Bart's disease, 398
 Haemoglobin C Harlem trait, 318

- Haemoglobin Constant Spring, 215, 216
 geographical distribution, 401-402
 molecular mechanism of, 266
 α thalassaemia and, 384, 402
- Haemoglobin F, 567-502
 abnormalities of the structure and synthesis of, 498-500
 chromosomal anomalies, 488
 clinical significance of, 293
 determination of, 544-549
 evaluation of methods, 548-549
 genetic control of, 472-475
 haemoglobin S/hereditary persistence of, 311-312
 hereditary persistence of, 280, 482
 Negro, Greek and Swiss types, 482-486
 persistent, in adults, 481-488
 relationship between structure and function of, 476-477
 synthesis, 501-502
 in β thalassaemia, 413
- Haemoglobin H, 390
 inclusion bodies in α thalassaemia, 387
 disease, 340-345
 geographical distribution, 400
- Haemoglobin Kenya, 499
- Haemoglobin Lepore, 448-450
- Haemoglobin-Lepore thalassaemia, 275
- Haemoglobin Olympia, 374
- Haemoglobin S, 288 ff
 hereditary persistence of fetal haemoglobin and, 311-312
- Haemoglobin S/ β thalassaemia, 308-309
- Haemoglobin S/C disease, 309-310
- Haemoglobin S/D Punjab disease, 310-311
- Haemoglobin S/O Arab disease, 311
- Heat denaturation test, 345
- Heat stability test, 551-552
- Heinz bodies, 342
 formation, mechanism of, 350-351
- Hybridisation of globin chains, 560
- IMMUNOLOGICAL characterisation in identifying haemoglobin abnormalities, 563-564
- Immunological method in diagnosis of α thalassaemia, 387
- Inclusion bodies, stains for, 527-528
- Infection, susceptibility to, in sickle-cell anaemia, 304-305
- Iron, in β thalassaemia, 416
- Iron chelation, 407
 in β thalassaemia, 431-432
- Isoelectric focussing, 534-535
- Isopropanol precipitation test, 552-553
- Isotope studies, 348
- LEUKAEMIA, haemoglobin F in, 491
- Leukaemia—(continued)
 juvenile chronic myeloid, 490-491
- Linkage—
 between haemoglobin genes, 254-255
 of the β -globin gene and the β -thalassaemia mutation, 450
- MALARIA, and sickle-cell disorders, 305
- Messenger RNA, 234-235
 and the thalassaemia defect, 455-457
 translational control and, 457-458
- Methaemoglobinaemia, 346
- Mutations, terminator, 460, *see also*
 Haemoglobin Constant Spring
- Myoglobin, 358-360
- NECROSIS, aseptic, in sickle-cell anaemia, 313
- Negro form of hereditary persistence of fetal haemoglobinaemia, 482-486
- Negro α thalassaemia/haemoglobin I, 396
- Negrees, haemoglobin S/ β thalassaemia in, 309
- Non-polar residues, replacement of by polar residues, 335
- Nuclear RNA metabolism, 451-453
- Nucleoprotein, in β thalassaemia, 421-422
- OPERON, 443
 regulating genes, and thalassaemia, 445
- Osmotic-fragility tests, 347
- Osteomyelitis in sickle-cell disease, 313
- Oxy-deoxy equilibrium within subunits, abnormalities affecting the, 370-371
- Oxy-haemoglobin S, mechanical instability of, 551
- Oxygen loading, mechanics of, 361-362
- Oxygen saturation, 559
- Oxygen transport, haemodynamics and, 299-300
- PCMB precipitation test, 553
- Penicillin, prophylactic after splenectomy in thalassaemia, 407
- Peptide analysis, 562-563
- pH determinations, 558
- PO₂ determinations, 559
- Polar residues, replacement of non-polar by, 335
- Priapism in sickle-cell disease, 315-316
- Proline, replacement of, 339
- Protein synthesis, 453-454
- Proteins, chromosomal, 438-440
- Pulmonary complications in sickle-cell anaemia, 315
- QUATERNARY structures, abnormalities affecting the equilibrium between, 371-374

- RED-cell life span, haemodialysis and, 301
 Red-cell metabolism, 347
 Red-cell production, 224-228
 Renal function, disordered, in sickling disorders, 305-306
 Rheology, abnormal in sickling disorders, 295-298
 RNA processing, 452-453
- SALT bonds, abnormalities involving, 368-370
- Sickle-cell anaemia, **288-322**, 486-487
 aplastic crisis, 312
 aseptic necrosis, 313
 clinical features, 299-305
 complications, 312-317
 dactylitis, 312
 fetal haemoglobin in, 293
 haematuria, 316
 incidence, 306
 liver disease, 316
 osteomyelitis, 313
 painful crisis, 313
 pathophysiology of, 289-290
 priapism, 315-316
 retinopathy, 316-317
 rheology of blood in, 295
 spleen in, 301-303
 treatment, 318
- Sickle-cell trait, 317-318
- Sickle-cell β thalassaemia, 308-309
- Sickle-cell haemoglobin C disease, 309-310
- Sickle-cell haemoglobin D disease, 310-311
- Sickling tests—
 evaluation of methods, 550-551
- Splenectomy, in α thalassaemia, 406-407, 431
 in β thalassaemia, 431
 in unstable haemoglobin disorders, 349
- Splenic dysfunction in sickle-cell disorders, 301-303
- Starch-block electrophoresis, 543
- Starch-gel electrophoresis, 530-532
- Sulphaemoglobinaemia, 346
- THALASSAEMIA—
 definition of, 272-279
 molecular defect in, **437-461**
- α thalassaemia, 276-279, **383-408**
 African, 278
 and Hb Constant Spring, 278
 classification of, 383-384
 clinical features, 384-399
 diagnosis, 386-387
 genetics of, 402-405
 geographical distribution of, 400-402
 haemoglobin H disease, 390-395
 in association with—
 α -chain haemoglobin variants, 395
 α thalassaemia—(continued)
 β -chain haemoglobin variants, 396
 β thalassaemia and hereditary persistence of fetal haemoglobin, 279, 399
 β or $\delta\beta$ thalassaemia, 399
 haemoglobin C, 399
 haemoglobin E, 396-398
 haemoglobin S, 398-399
 laboratory findings, 385-386
 major (see also Haemoglobin Bart's hydrops), 387-390
 management, 405-407
 socio-economic problems, 407-408
 traits, 384-385
 α thalassaemia 1/haemoglobin-Constant Spring disease, 395
 α thalassaemia 1/haemoglobin-Q disease, 396
 α thalassaemia 2/Hb-Constant Spring/Hb-E trait, 398
 α -thalassaemia trait/haemoglobin-E trait, 396-397
 α -thalassaemia trait/homozygous Hb E, 398
 β thalassaemia, 272-274, **411-433**
 α -chain excess in, 414
 asymptomatic, 429
 β -chain deficiency in, 412
 classification of, 413
 clinical aspects and forms of, 425-429
 compensatory mechanisms in, 424
 effects of on whole organism, 423-424
 in Ferrara, 457
 haematological findings, 422
 intermediate, clinical aspects, 427-429
 management, 429-432
 iron chelation, 431
 splenectomy, 431
 metabolic effects, 423
 pathophysiology of, 412-426
 δ thalassaemia, 275
 $\delta\beta$ thalassaemia, 274-275
 combination of with β thalassaemia, 275
 γ thalassaemia, 276
 $\gamma\beta$ thalassaemia, 500
 F thalassaemia, 274-275
 see also $\delta\beta$ -thalassaemia
 Transcription, 451-452
 Transcriptional regulation, 236-240
 Transcriptional unit, 440-445
 and erythropoiesis, 444
 Transfusion—
 in haemoglobin H disease, 406
 in sickling disorders, 318
 in β thalassaemia, 429-431
 Translational control, 241-242
 of mRNAs, 457-458
- UREA, and sickling disorders, 318-319

Index

Note: Page numbers of articles are in **boldface** type.

ANAEMIA

- and cardiovascular response to, 617-618
- and oxygen extraction by the tissues, 618-619
- and physical work capacity, **609-624**
- and respiratory response to exercise, 616-617
- estimates of the effect of on physical activity, 619-622
- functional considerations in, 613-616
- haematological normalcy and, 609-619
- iron deficiency, clinical symptoms, haemoglobin concentration and erythrocyte biochemistry, **689-702** (*see also* Iron deficiency anaemia)

Anaemic hypoxia, 602-604

BLOOD oxygen affinity, 2,3-DPG—

in vitro, 630-632

in vivo, 632-633

CARDIORESPIRATORY disease, red cell adaptation in, **627-644**

Cardiovascular disease, and haemoglobin levels, 711-713

Cardiovascular response to exercise, anaemia and, 617-618

Cyanotic heart disease, 634-638

2,3-DIPHOSPHOGLYCERATE(2,3-DPG)—

and in vitro blood oxygen affinity, 630-632

inappropriate concentration of in abnormal haemoglobin function, 591

2,3-diphosphoglycerate interaction, haemoglobin function and, 579-580

ERYTHROPOIETIN production during exposure to high altitudes, 601-602

Exercise—

anaemia and cardiovascular response to, 617-618

anaemic and respiratory response to, 616-617

HAEMATOLOGICAL normalcy—

and anaemia, 609-619

functional considerations, 613-616

Haemoglobin, adaptation to physical work with low levels of, 622-624

Haemoglobin function, and 2,3-DPG interaction, 579-580

Haemoglobin function, abnormal, 585-592

altered haemoglobin-ligand interaction in, 589-591

altered oxygen affinity, 585-587

altered shape of oxygen dissociation curve, 587-589

inappropriate concentrations of 2,3-DPG, 591

therapeutic considerations, 591-592

Haemoglobin levels, circulating—

and mortality, 713-716

approach to evaluating, **705-709**

clinical evaluation of, **705-717**

symptoms in low, 709

Heart disease—

cyanotic, 634-638

noncyanotic, 630-633

Hypoxia—

anaemic, 602-604

red cell oxygen affinity and erythropoietin production, **595-605**

the red cell in adaptation to anaemic, **577-592**

INFECTION, and haemoglobin levels, 710

Iron deficiency anaemia, study in women with, **689-702**

biochemical findings, 695-698

haematological findings and specificity of the diagnosis of, 693-695

materials and methods used in, 693-701

results, 693-701

symptoms correlated with haematological and erythrocyte biochemical variables in, 698-701

LUNG disease in adults and older children, 638-639

MYOCARDIAL insufficiency in dogs, effect of preserved red cells with increased affinity for oxygen, 663

NEONATAL respiratory distress syndrome, 639-640

Noncyanotic heart disease, 630-633

OXYGEN affinity—

and regulation of oxygen binding capacity, 599-601

consequences of changes in, 640-643

- Oxygen affinity of human red cells—
and oxygen transport to the tissues, 597–598
regulation of, 595–597
- Oxygen binding capacity—
and oxygen transport, 598–599
oxygen affinity and regulation of, 599–601
- Oxygen transport, oxygen binding capacity and, 598–599
- Oxygen transport function of preserved red cells, 649–682, 664–668
- PHYSICAL activity, estimates of the effect of anaemia on, 619–622
- Physical work, adaptation to with low levels of haemoglobin, 622–624
- Populations, haematological characteristics of, and therapeutic and supplementation studies, 609–612
- RED cell—
adaptation in cardiorespiratory disease, 627–644
in adaptation to anaemic hypoxia, 577–592
- Red cell affinity for oxygen—
in vitro measurements of, 652–653
in vivo measurements of, 651–652
- Red cell 2,3-DPG, regulation of, 580–582
- Red cell function, normal, 578–584
- Red cell mass, reduction in, 582–584
- Red cells—
oxygen transport function of preserved, 649–682, 664–668
physiological effect of human, with increased affinity for oxygen, 653–663
regulation of the oxygen affinity of human, 595–597
with above normal 2,3-DPG levels and decreased affinity for oxygen, therapeutic effectiveness of, 669–681
with increased affinity for oxygen, effect of on myocardial insufficiency in dogs and on work performance in rats, 663
- Respiratory distress syndrome, neonatal, 639–640
- Respiratory response to exercise, anaemia and, 616–617
- TRANSFUSION, exchange, in newborn infant, 663
- WORK capacity—
anaemia and physical, 609–624
and haemoglobin levels, 710
- Work performance in rats, effect of preserved red cells with increased affinity for oxygen, 663

